Estrogen Therapy in United Kingdom 2026
Hormone replacement therapy has quietly become one of the biggest turnaround stories in modern British medicine. After years of caution following early-2000s safety scares, estrogen-based HRT prescribing has more than doubled in the UK since 2018, and 2026 marks the point where this revival has fully entered mainstream healthcare policy rather than staying a niche prescribing trend. Nearly 15 million HRT items were dispensed in England in 2024/25 alone, an 11% year-on-year increase, and the government has now moved to include menopause advice in routine NHS health checks for the first time — a genuine landmark shift in how the health service treats a life stage that affects roughly a third of the entire UK female population.
What makes the current moment particularly significant is the scale of the demographic shift behind these numbers. Women aged 45-54 are now the fastest-growing group in the UK workforce, meaning millions of working women are navigating perimenopause and menopause symptoms while balancing careers at the same time their symptom burden, and their HRT usage, is climbing fastest. This article draws together the latest verified UK data for 2026 — prescribing volumes, the specific estrogen formulations driving growth, access inequalities by ethnicity and deprivation, and the very real economic and workplace cost of untreated menopause — to give you one accurate, up-to-date picture of where estrogen therapy in Britain currently stands.
Estrogen Therapy Facts UK 2026
| Fact | Figure |
|---|---|
| HRT items dispensed in England, 2024/25 | Nearly 15 million |
| Year-on-year increase in HRT prescriptions (2024/25 vs 2023/24) | 11% |
| Patients identified as receiving HRT (2024/25) | 2.8 million |
| Rise in patients receiving HRT (year-on-year) | 6.4% |
| Women aged 45-54 with an estrogen-based HRT prescription | 1 in 20 (nearly 5%) |
| Increase in estrogen-based HRT use, women aged 45-54 | 184.2% rise since study start |
| Women in UK estimated to go through menopause | Over 33 million |
| Women reporting menopausal symptoms | Approximately 90% |
| UK women currently on HRT | Roughly 1 in 7 (14%) |
| Annual cost of HRT Prescription Prepayment Certificate | £19.80 |
Source: NHS Business Services Authority (NHSBSA), Truveta Research, Chemist4U 2025/26 Menopause Statistics Report
The nearly 15 million HRT items dispensed in England in 2024/25 is the single clearest indicator of just how far hormone therapy has come back into favour with both prescribers and patients, representing an 11% year-on-year jump that shows no sign of plateauing. Behind that headline figure sits a more specific and arguably more revealing statistic: prescribing rates for estrogen-based HRT among women aged 45-54 rose by 184.2%, to the point where roughly 1 in 20 women in this age bracket now has evidence of an active estrogen-based prescription, a dramatic reversal from the caution that defined HRT prescribing for much of the 2010s.
What these numbers also expose is a persistent gap between symptom prevalence and treatment uptake. With around 90% of the more than 33 million UK women expected to go through menopause reporting some form of symptoms, but only roughly 1 in 7 women currently using HRT, there’s a substantial population of symptomatic women who either haven’t sought treatment, have been unable to access it, or have chosen not to pursue it. The £19.80 annual HRT Prescription Prepayment Certificate, which allows unlimited prescriptions for qualifying medicines, has become an increasingly important access point — though as later sections show, uptake of that certificate and of HRT prescribing more broadly is far from evenly distributed across the population.
HRT Prescribing Trends in UK 2026
| Metric | 2023/24 | 2024/25 |
|---|---|---|
| Total HRT items prescribed (England) | ~13.2 million | ~14.7 million |
| Patients receiving HRT | 2.6 million | 2.8 million |
| Estradiol 0.06% gel items dispensed | ~1.15 million | 1.3 million |
| HRT PPC share of all HRT items | ~14% | 21% |
Source: NHS Business Services Authority, Hormone Replacement Therapy Statistics – England: April 2015 to June 2025
The most recent NHSBSA data confirms the trajectory has been consistently upward rather than a one-off spike: annual HRT prescription items in England climbed from around 13.2 million in 2023/24 to nearly 14.7 million in 2024/25, alongside a rise in the total patient count from 2.6 million to 2.8 million over the same period. Estradiol 0.06% gel remained the single most frequently prescribed formulation, with 1.3 million items dispensed, a 13% increase on the previous year, reflecting a broader clinical and patient preference shift toward transdermal delivery methods over older oral tablet formulations.
Perhaps the most telling operational statistic in this year’s data is the growth in use of the HRT Prescription Prepayment Certificate, which rose to account for 21% of all HRT items dispensed in 2024/25, up nearly seven percentage points from the year before. This uptake shows that cost has been a meaningful barrier for many long-term HRT users, and that as awareness of the £19.80 annual certificate has spread, patients have actively restructured how they pay for ongoing treatment. It’s worth noting that the NHSBSA also identified over 200,000 prescriptions wrongly claimed using the HRT PPC between June 2024 and May 2025, a compliance issue significant enough to prompt scrutiny even as underlying prescribing continues to grow.
Estrogen Formulation and Route Statistics in UK 2026
| Formulation Type | Growth Trend (2018-2026) |
|---|---|
| Estrogen patches | More than tripled |
| Vaginal creams | Increased more than fourfold |
| Combination oral/transdermal (oestrogen + progesterone) | 62.4% of all prescriptions are combination formulations |
| Oral formulations | 43.3% of prescriptions |
| Transdermal formulations | 26.3% of prescriptions |
Source: Truveta Research analysis of estrogen-based HRT prescribing, 2018-early 2026; BMJ Medicine cohort study, UK primary care
Among all the shifts in how estrogen therapy is being prescribed in Britain, the change in delivery method stands out as the most consistent trend across every major dataset. Estrogen patch use has more than tripled since 2018, while vaginal cream prescriptions have increased more than fourfold over the same period, reflecting both clinical guidance favouring non-oral routes for many patients and growing patient preference for localized or steady-release options over daily tablets. Combination formulations containing both oestrogen and progesterone remain the most commonly prescribed HRT type overall, accounting for 62.4% of all prescriptions, split between 43.3% oral and 26.3% transdermal delivery.
This move toward non-oral formulations isn’t simply a matter of convenience — transdermal and vaginal routes are associated with different risk profiles compared with oral estrogen, particularly around venous thromboembolism risk, which has made them an increasingly common first-choice recommendation in UK primary care guidance. The mean age at first HRT prescription across recent UK cohort data sits at 49.8 years, closely tracking the average onset of perimenopausal symptoms, which suggests that GPs are broadly succeeding at initiating treatment reasonably close to symptom onset for the patients who do access care — even though, as the next section shows, that access is anything but equal across the population.
HRT Access Inequality Statistics in UK 2026
| Group | HRT Uptake / Prescribing Pattern |
|---|---|
| White women | 22.6% received two or more HRT prescriptions |
| Caribbean women | 8.9% |
| Black African women | 3.9% |
| London region | 11.7% (lower than all other UK regions) |
| Other UK regions | All above 19% |
| Least deprived areas | More than twice the prescribing rate of most deprived areas |
Source: BMJ Medicine, “Inequalities in hormone replacement therapy prescribing in UK primary care,” population-based cohort study of 1,978,348 women
A landmark BMJ Medicine cohort study covering nearly 2 million women aged 40-60 in UK primary care has confirmed what many menopause specialists had long suspected: HRT access in Britain is significantly shaped by ethnicity, deprivation, and geography rather than symptom severity alone. White women received two or more HRT prescriptions at a rate of 22.6%, compared with just 8.9% among Caribbean women and 3.9% among Black African women, disparities that persisted even after the researchers statistically adjusted for other socioeconomic factors. London stood out as having the lowest regional prescribing rate at 11.7%, notably below every other UK region, all of which recorded rates above 19%.
Deprivation compounds these ethnic disparities rather than operating independently of them: patients in the least deprived areas are more than twice as likely to receive HRT prescribing as those in the most deprived areas, according to NHSBSA data, and the BMJ Medicine study found that each incremental increase in social deprivation was statistically associated with a measurably lower likelihood of receiving a prescription. Researchers behind the study were explicit that these gaps reflect genuine inequities in access rather than differences in underlying need, since menopause itself doesn’t discriminate by ethnicity or postcode — which means the current HRT revival, while real and substantial in aggregate, is still being experienced unevenly across different communities in the UK. For a broader look at how chronic condition treatment gaps track alongside deprivation more generally, the Heart Disease Statistics in UK report shows a similarly persistent socioeconomic pattern running through cardiovascular care access.
Menopause Workplace and Economic Impact Statistics in UK 2026
| Metric | Figure |
|---|---|
| Women aged 40-60 in UK workforce | ~7 million |
| Women who considered quitting due to menopause/menstrual symptoms | 23% |
| Women actively planning to quit | 14% |
| Women who left the workforce in 2023 due to menopause symptoms | ~1 million (estimated) |
| Women not in employment due to peri/menopause | ~60,000 |
| Direct annual economic cost to UK economy | £1.5 billion |
| Working women reporting negative impact on concentration | 52-79%, depending on survey |
Source: CIPD Menopause Workplace Experiences report; Simplyhealth workplace research; NHS Confederation economic impact analysis
The economic and workplace toll of unmanaged menopause symptoms in the UK is substantial enough that it’s now treated as a genuine labour market issue rather than a private health matter. An NHS Confederation analysis estimated the direct economic impact of menopause-related unemployment at approximately £1.5 billion per year, driven by roughly 60,000 women in the UK currently not in employment because of perimenopause or menopause symptoms. Survey data from Simplyhealth found that 23% of working women have considered quitting their job due to menopause or related symptoms, with 14% actively planning to leave, figures that sit alongside CIPD’s finding that two-thirds of employed women aged 40-60 say their symptoms have had a mostly negative effect on them at work.
This economic pressure lands at a particularly costly point in most women’s careers, since women aged 45-54 are now the fastest-growing demographic in the UK workforce, meaning the peak of menopausal symptom burden is increasingly coinciding with the peak of many women’s professional seniority and earning potential. Symptom-related productivity effects are wide-ranging and well-documented across multiple surveys: over half of working women report reduced concentration, roughly two-fifths say symptoms affect their day-to-day productivity, and a majority report having lost confidence or motivation as a direct result. Understanding this scale of workforce impact is part of why NHS staffing and retention strategies increasingly reference menopause support as a workforce planning issue, a theme that connects to the broader staffing pressures explored in the NHS Workforce Statistics report, where recruitment and retention challenges remain a persistent theme across the health service.
Perimenopause and Early Symptom Statistics in UK 2026
| Metric | Figure |
|---|---|
| UK women currently peri- or menopausal | ~13 million (1/3 of UK female population) |
| Average age of menopause in UK | 51 years old |
| Perimenopause duration range | 2 to 8 years |
| Women reporting loss of motivation from symptoms | 61% |
| Women reporting loss of confidence from symptoms | 52% |
| Women who felt menopause was treated as a joke at work | 41% (rising to 54-58% among specific subgroups) |
Source: NHS England Citizen Space consultation; Chemist4U Menopause Statistics 2025-26; Wellbeing of Women
Roughly 13 million people in the UK are currently peri- or menopausal at any given time, equivalent to a full third of the entire UK female population, with the average age of menopause onset sitting at 51 years old. The perimenopausal transition preceding this can last anywhere from two to eight years, meaning many women are managing fluctuating symptoms for the better part of a decade before reaching menopause itself — a duration that’s part of why earlier diagnosis and treatment initiation has become such a clinical priority, and why the current wave of estrogen therapy uptake is increasingly starting during perimenopause rather than being delayed until after periods stop entirely.
The psychological and social dimension of these symptoms shows up clearly in the survey data too. 61% of women reported losing motivation and 52% reported losing confidence as a direct result of their symptoms, while a striking 41% said they had seen menopause treated as a joke in the workplace, a figure that climbed to 54% among women not currently in work during menopause and 58% among those with a disability. These figures underline why the current UK policy shift toward including menopause advice in routine NHS health checks matters beyond the purely medical dimension — for a related look at how perimenopause specifically is being recognised and treated earlier in the UK healthcare system, the Perimenopause Symptoms and Treatment report covers the specific signs GPs are now trained to identify well before full menopause sets in.
What’s changing fastest heading into the second half of 2026 is the framing around when treatment should actually start. For years, UK clinical practice tended to treat HRT as something initiated once full menopause had been confirmed, but the 2-to-8-year perimenopausal window is now increasingly recognised as the period where early intervention delivers the most benefit, particularly for symptoms like sleep disruption, mood changes, and cognitive fog that can otherwise compound over time. NICE guidance updates and increased GP training on perimenopause recognition have both played a role in shifting the mean age at first HRT prescription toward 49.8 years, closer to the earlier end of the typical symptom-onset range rather than several years after symptoms first appear.
This earlier-intervention shift also helps explain part of the prescribing growth documented throughout this report, since a meaningful share of the 184.2% increase in estrogen-based HRT use among women aged 45-54 likely reflects perimenopausal patients starting treatment sooner rather than only capturing new post-menopausal patients. Taken together with the £1.5 billion annual economic cost of menopause-related workforce departures and the persistent ethnic and regional access gaps documented in the BMJ Medicine cohort study, the picture for 2026 is one of genuine progress on treatment uptake running alongside work still needed to make that progress reach every community and region equally.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
